Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Central Nervous System Neoplasm

erlotinib hydrochloride has been researched along with Central Nervous System Neoplasm in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (13.33)29.6817
2010's13 (86.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
He, H; He, X; Lan, BH; Li, MX; Li, RQ; Liu, GD; Ruan, ZH; Wang, G; Wu, Y; Xiao, HL; Yang, ZZ; Zhang, ZM; Zhu, B; Zhu, YX1
Cavenee, WK; Cloughesy, TF; Eskin, A; Furnari, FB; Gini, B; Gomez, G; Heath, JR; Hwang, K; James, CD; Koga, T; Kornblum, HI; Masui, K; Mischel, PS; Mottahedeh, J; Nathanson, DA; Nelson, SF; Ohashi, M; Paucar, A; Rao, PN; Reed, R; Visnyei, K; Wang, J; Wykosky, J; Yang, H; Zhu, S1
Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC1
Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, RE; Norfleet, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ1
Chang, J; Cho, BC; Choi, HJ; Kim, JH; Kim, SK; Lee, YJ; Moon, JW; Park, IK1
Ishida, T; Iwasaku, M; Kunimasa, K; Nishiyama, A; Ubukata, S; Yoshioka, H1
Fujita, S; Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y1
Kaelin, W; LoRusso, P; Malik, G; Nadler, P; Rogers, LR; Shields, A1
Britt, GJ; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Rabin, MS; Yeap, BY1
Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y; Tsuchido, Y1
Clarke, JL; Grommes, C; Holodny, AI; Kris, MG; Lassman, AB; Miller, VA; Oxnard, GR; Pao, W1
Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY1
Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Masuda, S; Mishima, M; Mizuno, T; Nagai, H; Sakamori, Y; Togashi, Y1
Codacci-Pisanelli, G; Della Rocca, C; Frati, L; Gulino, A; Lo Russo, G; Miele, E; Miscusi, M; Papa, A; Petrozza, V; Spinelli, GP; Tomao, S1
Cappuzzo, F1

Reviews

1 review(s) available for erlotinib hydrochloride and Central Nervous System Neoplasm

ArticleYear
Chemotherapy and target therapy in the management of adult high- grade gliomas.
    Current cancer drug targets, 2012, Volume: 12, Issue:8

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Central Nervous System Neoplasms; Cetuximab; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Nitrosourea Compounds; Organophosphorus Compounds; Promoter Regions, Genetic; Quinazolines; Temozolomide; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins

2012

Trials

2 trial(s) available for erlotinib hydrochloride and Central Nervous System Neoplasm

ArticleYear
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
    Journal of neuro-oncology, 2010, Volume: 96, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome

2010
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome

2012

Other Studies

12 other study(ies) available for erlotinib hydrochloride and Central Nervous System Neoplasm

ArticleYear
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    BMC cancer, 2017, 04-04, Volume: 17, Issue:1

    Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Quality of Life; Quinazolines

2017
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.
    Science (New York, N.Y.), 2014, Jan-03, Volume: 343, Issue:6166

    Topics: Animals; Antineoplastic Agents; Central Nervous System Neoplasms; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Molecular Targeted Therapy; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Single-Cell Analysis; Tumor Cells, Cultured; Withholding Treatment

2014
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
    The European respiratory journal, 2009, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome

2009
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
    Cancer, 2010, Mar-01, Volume: 116, Issue:5

    Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Korea; Male; Protein Kinase Inhibitors; Quinazolines

2010
[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2010, Volume: 48, Issue:2

    Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome

2010
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome

2010
Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report.
    Journal of neuro-oncology, 2011, Volume: 101, Issue:2

    Topics: Adult; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Hemangioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; von Hippel-Lindau Disease

2011
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Dec-01, Volume: 16, Issue:23

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome

2010
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:4

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines

2011
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
    Neuro-oncology, 2011, Volume: 13, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome

2011
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Aug-15, Volume: 18, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors

2012
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
    Journal of the National Cancer Institute, 2005, Jun-15, Volume: 97, Issue:12

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Patient Selection; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines

2005